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Abstract 
In this work, biocompatible and biodegradable poly(D-L-lactide-co-glycolide) (PLGA) microparticles 
with the potential for use as a controlled release system of vaccines and other drugs to the lung were 
manufactured using supercritical CO2, through the Supercritical Assisted Atomization (SAA) 
technique. After performing a controlled variance in production parameters (temperature, pressure, 
CO2/solution flow ratio) PLGA microparticles were characterized and later used to encapsulate active 
pharmaceutical ingredients (API). Bovine serum albumin (BSA) was chosen as model protein and 
vaccine, while sildenafil was the chosen drug to treat pulmonary artery hypertension and their effect 
on the particles characteristics was evaluated. All the produced formulations were characterized in 
relation to their morphology (Morphologi G3 and scanning electronic microscopy (SEM)), to their 
physical-chemical properties (X-ray diffraction (XRD, differential scanning calorimetry (DSC), 
Fourier transform infrared (FTIR)) and aerodynamic performance using an in vitro aerosolization 
study – Andersen cascade impactor (ACI) - to obtain data such as the fine particle fraction (FPF) and 
the mass median aerodynamic diameter (MMAD). Furthermore, pharmacokinetic, biodegradability 
and biocompatibility tests were performed in order to verify the particle suitability for inhalation. The 
resulting particles showed aerodynamic diameters between the 3 and 5 μm, yields up to 58% and FPF 
percentages rounding the 30%. Taken as a whole, the produced microparticles do present the 
necessary requests to make them appropriate for pulmonary delivery. 
 
Keywords:  Microparticles; Pulmonary delivery; Poly(lactic-co-glycolic acid); Supercritical Assisted 
Atomization. 
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Resumo 
Neste trabalho, desenvolveram-se micropartículas de ácido poli(láctico-co-glicolídico) (PLGA)  
biocompatíveis e biodegradáveis com potencial uso como sistemas de libertação controlada de vacinas 
e outros fármacos , através da técnica de atomização assistida por CO2 supercrítico (SAA). Depois de 
variar controladamente os parâmetros de produção (temperatura, pressão, rácio CO2/solução), as 
micropartículas de PLGA foram caracterizadas e posteriormente utilizadas para encapsulação de 
princípios ativos. A albumina do soro bovino (BSA) foi escolhida como proteína e vacina modelo 
enquanto o sildenafil foi escolhido como o fármaco para tratar a hipertensão arterial pulmonar, e foram 
avaliados os efeitos de ambos nas características das partículas. Todas as formulações produzidas 
foram caracterizadas em relação à sua morfologia (Morphologi G3, espectroscopia eléctronica de 
varrimento (SEM)), às suas propriedades físico-químicas (difracção de raio-X (DRX), calorimetria 
diferencial de varrimento (DSC), espectroscopia de infravermelho (FTIR)) e ao seu desempenho 
aerodinâmico usando um estudo de aerossolização in vitro – Andersen cascade impactor (ACI) - para 
obter valores tais como fração de partículas finas (FPF) e o diâmetro aerodinâmico mediano de massa 
(MMAD). Para além disso, executaram-se testes farmacocinéticos, de biodegradação e de 
biocompatibilidade para verificar se as partículas são adequadas para inalação. As partículas obtidas 
mostram diâmetros aerodinâmicos entre 3 e 5 μm, rendimentos até os 58% e percentagens de FPF a 
rondar os 30%. Em geral, as micropartículas produzidas apresentam os requerimentos necessários que 
as fazem apropriadas para administração via pulmonar. 
 
Palavras-Chave: Micropartículas; Administração pulmonar; Ácido poli(láctico-co-glicolídico); 
Atomização assistida por fluídos supercríticos. 
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1. Introduction 
The routes of drug administration usually reach lungs, skin and intestinal tract, since these organs have 
a direct contact with the exterior. Even though the oral route is simple and the most common one, it 
has a risk of drug decomposition by digestive system. The transdermal route is also simple, but an 
adsorption efficiency of drugs is generally low in this method.  Injections result in high adsorption 
efficiency, an early effect of injected drugs’ pharmacological actions, and no risk of drug 
decomposition by digestive organs. However, because this is an invasive method, it provokes 
discomfort to patients.
1
 
The local application of drugs to the respiratory tract via inhalation facilitates a site specific treatment 
of lung diseases (asthma, chronic obstructive pulmonary disease (COPD)) with lower systemic 
exposure and consequently, reduced side effects. Yet again, it is also an advantageous route for 
systemic drug delivery since it shows a high solute permeability, due to its very thin absorption 
membrane (0.1-0.2 μm), to its elevated blood flow (5L/min) and to the highly vascularized alveolar 
epithelium constituted by a single layer of cells, which offers a large absorptive surface (80–100 m
2
). 
All this facilitates the distribution of the molecules throughout the body.
2,3
 It also has an easy 
administration, shows early effects of drugs’ pharmacological actions and has no risk of drug 
decomposition.
4
 The absorption of macromolecules via the pulmonary route is rapid and facilitated by 
the highly vascularized alveolar epithelium. Also, unlike the oral route, it is not subject to first pass 
metabolism which is especially important to macromolecules (i.e. peptides and proteins) that are easily 
degraded by enzymes.
5
 
However, the short duration of drug action in the lung is considered a significant disadvantage of 
conventional inhalation therapy. Hence, the development of pulmonary controlled release formulations 
would be highly beneficial for patients suffering from lung diseases. Controlled drug release systems 
composed of polymeric materials with particular characteristics, such as biocompatibility and 
degradability, have been shown to improve the pharmacokinetic and pharmacodynamic profiles of 
encapsulated drugs in the lung.
1,4
 
The use of dry powders as drug delivery systems has been increasingly considered as a treatment 
option, even though it brings out concerns related to respiratory tract anatomy, breathing pattern and 
particle size.
6
  
Ideally, dry powders should have high dispersibility, drug stability, narrow size distribution and 
sustained release. Above all, there is a need to control both size and morphology of the particles since 
those are the characteristics that affect drug deposition.  There is also a need to make sure that the 
particles have a physical stability in order to prevent unfavorable solid-state transitions.
7
 
 
 
 
2 
 
1.1 Vaccines 
Vaccine is an antigenic preparation used to establish immunity to a disease, which when administered 
to humans, provides protection against such disease by the activation of T and B cells.
8
 The future of 
vaccines extend beyond the treatment of infectious diseases and it has been already used for cancer 
immunotherapy, being the first cancer vaccine licensed in 2010.
9
 Vaccines are responsible for a big 
part of the death prevention associated with numerous infection diseases every year, even though there 
is still a huge amount of children morbidity due to vaccine-preventable diseases.
10
 This happens 
because those children are mostly from developing countries, and vaccines nowadays are mainly 
delivered via a parenteral route, which is not the most appropriate to overcome this issue. Vaccines 
administered parenterally require expensive cold chain transport and trained personnel, and they can 
induce needle-stick injuries with possible transmission of viruses.
11,12
 To treat the infectious diseases 
that affect poor populations the vaccines should be simple, cheap, easy to produce and stable. This is 
all possible with pulmonary vaccination added to all the advantages for drug delivery already 
mentioned.
13
 Above that is the fact that the lungs have gained a lot of attention given that the 
respiratory tract is the main entry of pathogens and also it has an extensive dendritic cell network 
lining the airway epithelium that facilitates a first line of defense for antigens.
14
 The ideal vaccine 
formulation would be one delivered in a single dose, and it is known that microparticles efficiently act 
as immune system adjuvants by carrying antigenic materials and by depositing them in the bronchiolar 
region, so the exposure to the antigen can be increased.
13,15
 Even though it has already been proven 
that the pulmonary delivery of antigens induces immunity, there are still no dry powder vaccines on 
the market and the major difficulty is the adaptation of the parenteral formulation for the lung safety 
and efficacy.
12
  Despite that, there are several known pulmonary vaccines already produced for such 
diseases as tuberculosis
16
, influenza
11
, measles
17
 and hepatitis B.
18
  
 
1.2 Pulmonary Arterial Hypertension  
Pulmonary Arterial Hypertension (PAH) is characterized by heavily proliferation and apoptosis 
resistance of vascular cells of the lung (smooth-muscle cells, fibroblasts and endothelial cells), 
reducing the area of small pulmonary arteries and stiffening large pulmonary arteries that have as a 
consequence the increase of pulmonary vascular resistance and  artery pressure.
19
 This condition is 
normally associated with connective-tissue diseases, congenital heart disease, protopulmonary disease 
and HIV. Its cause is not always sure, it can occur either due to genetic mutations in the bone 
morphogenetic protein type II receptor (BMPR-II) that will affect the growth-suppressive effect of the 
bone morphogenetic protein (BMP) or even because of environmental factors (drugs, toxins, 
viruses).
19,20
 The diminishing production of endothelial nitric oxide and the increase of the 
phosphodiesterase type 5 (PDE5) are the main pathologic features of PAH. While the nitric oxide 
stimulates the production of soluble cyclic guanosine monophosphate (cGMP) - an important 
 
3 
 
vasodilator and antiproliferative pathway in the pulmonary circulation, PDE5 is responsible for its 
hydrolysis. Without cGMP the levels of intracellular calcium and potassium rise and lead to 
vasoconstriction, proliferation of smooth-muscle cells and resistance to apoptosis.
21
 
PAH treatments normally use diuretics, anticoagulation, vasodilative or antiproliferative agents. 
Sildenafil (    Figure 1.1(a)), a PDE5 inhibitor used for the treatment of erectile dysfunction, is one of 
the most used therapeutic options that promotes apoptosis, reduces hyperoxia-induced lung injury, and 
augments pulmonary capillary density. The local delivery of sildenafil using the inhalation route 
allows for a reduction of drug exposure and shows more effectiveness than other routes thanks to the 
well-ventilated parts of the lung.
22,23
   
To deliver sildenafil to the lung, it should be encapsulated using a carrier in order to maintain its 
stability and also to have a controlled release.
4
 Dendrimers are synthetic polymers with a well-defined 
hyperbranched three-dimensional structure constituted by several layers as represented in     Figure 
1.1(b). Being able to have a nanoscale size, they are excellent carriers to use in a wide range of 
medical applications. They have been mainly used to deliver DNA drugs into the cell through the lung, 
but their use has been enlarged to other type of treatments.
24,25
 One example is the Polyurea (PURE) 
dendrimers that are biocompatible, biodegradable and “green” dendrimers whose fluorescence is very 
valiable for cell imaging or biosensing.
26
  
 
 
 
 
 
 
 
 
 
 
 
 
The use of nanoparticles as drug release systems has been considered because of their ability to protect 
drugs at both extracellular and intracellular levels and then release them in a sustained and controlled 
manner, and especially for the fact that they are still able to penetrate into deep tissue and then suffer 
cellular uptake. However, nanoparticles are not in between the optimal particle size for inhalation (1-
5μm) and are easily exhaled, so to improve both their aerodynamic properties and stability, they can 
be microencapsulated using an excipient.
27
   
 
    Figure 1.1 - Sildenafil (a) and a G3 Dendrimer
25
 (b) structures. 
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1.3 Dry Powder Inhalers 
For it to be a good delivery device, an inhaler should generate an aerosol of a suitable size (1-5 μm) 
with a reproducible drug dosing that makes sure the drug chemical stability and activity are intact. 
Also, this device should be simple, easy to use, inexpensive and portable.
3
 Taking these characteristics 
into account, Table 1.1 represents a comparison between the three existing inhalers.  
 
Table 1.1 – Comparison between the different inhalers relatively to different characteristics. 
 Nebulizers pMDI DPI 
Delivery efficiency + - + 
Ease of use - - + 
Portability - + + 
Drug stability - - + 
 
The first inhalers to be developed and to appear on the market were the nebulizers, in which the drug 
is dissolved in a polar liquid. However they showed some disadvantages such as low efficiency and 
reproducibility, the required time to the administration was about 30 minutes and their use was 
confined to hospitals or home, given that they were not portable.
2,3
 
To surpass these issues, the pressurized metered dose inhalers (pMDIs) were developed since they 
show greater efficiency and reproducibility, they are faster to use and also portable. Despite that, they 
also show some drawbacks since they require the use of compressed volatile liquids as propellants (i.e. 
chlorofluorocarbon), making them environmentally unfriendly, and because they deliver the dose at 
high velocity it facilitates the deposition in the oropharynx.
28
 
In order to overpass these problems, the inhalers were improved, and dry powder inhalers (DPIs) 
appeared (Figure 1.2). Besides being easy to use and portable, they are also propellant-free, making 
them environmentally friendly. Also, since the aerosols are in a dry state they assure the stability of 
the drug, needing no special condition storage and distribution.
29
 As for the delivery of vaccines these 
devices are very suitable once macromolecules (polysaccharides, proteins and peptides) tend to 
degrade when in a liquid solution and so are provided with a greater stability. That was proven by the 
production of a dry powder influenza vaccine by spray-freeze drying that showed an increase of the 
systemic and mucosal humoral and cell-mediated immune response in mice when compared with 
liquid vaccines.
11
 
However, they are expensive, complex to develop and the uniformity of the doses depends on the 
patient’s inspiratory flow because that is what set the particles in motion, provoking turbulence and 
shear in order to generate the aerosol. The particles then enter the patients airways and are carried to 
the deep lung.
30
 These devices are divided in “single-dose” DPIs, which use a single dose capsule, in 
“multiple unit dose” DPIs, which contains small doses separated in several capsules or blisters and in 
“multidose” DPIs that contain an amount of powder that is then delivered in several metered doses.
31
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Figure 1.2 - Schematic representation of (a) a person using an inhaler 
32
 and  (b)an example of a dry powder 
inhaler.
33
 
 
1.4 Characterization of inhaled particles 
In order to understand where particles with different size deposit in the respiratory tract, the 
aerodynamic diameter (da) it has to be taken into account and is defined by the equation (1) 
      
  
   
    (1) 
Where ρ is the mass density of the particle,     is the unit density and   the particle dynamic shape 
factor.
2
 
Though some conflicts regarding the range for optimal da to efficiently reach the deep lungs may exist, 
the most recent works states that the aerodynamic diameter of aerosol particles should be between 1 
and 5 µm since these size range is the one that gets to the deep lungs (Figure 1.3). While smaller 
particles may fail to deposit and are exhaled, bigger ones may accumulate in the mouth and throat by 
inertial impaction. The particles in between should deposit in the deep lung by inertial impaction and 
sedimentation.
34–36
 
Moreover, smaller particles are more likely phagocytized and have the tendency to aggregate due to 
van der Waals and electrostatic forces
37
, making large porous particles with low density suitable for 
lung delivery.
38
 Large porous particles have a mean diameter bigger than 5 μm and an associated low 
mass density, so even though these particles have large geometric diameters, they exhibit aerodynamic 
diameters comparable to smaller particles due to their low density. Since they have large sizes, these 
particles will avoid clearance by alveolar macrophages, enabling sustained drug delivery through the 
lungs. Furthermore, increasing the geometric diameters would increase the dispersibility and 
entrainment of the drug particles from the inhaler and finally they would tend to de-aggregate much 
easier than small non-porous particles.
5,7
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Figure 1.3 - Representation of the different stages of the respiractory tract and the particles’ deposition 
according to size. Adapted from Ungaro F. et al.
39
 
The mass median aerodynamic diameter (MMAD) is the particle diameter that can be obtained with 
the use of an in vitro aerosolization study such as a multistage cascade impactor, and it corresponds to 
50% of the cumulative distribution. With the same apparatus it is possible to calculate the fine particle 
fraction (FPF) that is the mass of particles under a cut-off diameter of around 5 μm and with the use of 
a dosage unit sampling apparatus (DUSA) the shot weight can be determined, which is the proportion 
of powder that exits the capsule.
40
 
In regards to inhaler products’ testing, the Andersen cascade impactor (ACI) and the next generation 
impactor (NGI) are the recommended by both the European and US pharmacopeia, since the airflow 
and differential pressure over the inhaler are easily controlled.
41,42
 ACI is a sizing sampler containing 8 
aluminium stages, each with a collection plate and a filter, and an induction port with a suitable mouth 
piece adapter. At times a pre-separator is used to collect large masses of non-respirable powders. The 
air flow rate should provide a pressure drop of 4 KPa with a defined time that allows the passage of 4 
liters of air through the ACI. The inhaled aerosol will be fractionated into different stages that have a 
decrease in the nozzles’ diameter throughout the apparatus as represented in Figure 1.4. The particles 
deposition on each collection plate will depend on their size and density, and subsequently their 
inertia, being the particles with larger da collected in the early stages and the smaller ones on the 
last.
41,43
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Figure 1.4 - Representation of the Andersen cascade impactor as well as its different stages and respective cut-
off diameters at 60 L/min, adapted from Mitchell, J. P. et al.
44
 
 
In order to provide a sustained controlled release, drug-polymer systems were produced and because 
of that the release of the drug is dependent not only in the diffusion rate from the non-degraded 
polymer, but also by its swelling and erosion. 
By modeling the drug release using mathematical equations, important information regarding mass 
transport and chemical processes relatively to the drug delivery system can be acquired, coupled with 
the effect of the parameters, for instance particle geometry or drug loading.
45
 
When it comes to model the drug release out of polymeric matrices, the Korsmeyer-Peppas equation 
(2) has been the most used one, even though it stands on a simple method to study only the importance 
of the diffusional exponent, n, which indicates the transport mechanism. The mechanism can either be 
due to the Fickian diffusional release (n=0.43) or polymer’s swelling (n=0.85). It also considers a k 
that is a constant incorporating characteristics of the macromolecular network system of the drug.
46
 
However, it is only valid to the first 60% of the release, because the further release is dependent on 
other factors that are not taken into account, such as particles degradation.  
 
  
  
 = k     (2) 
 
Notwithstanding, taking the Peppas and Sahlin equation (3) in consideration, two competing release 
mechanisms are taken into account: Fickian diffusional release and the Case-II relaxation release that 
corresponds to the second part of the equation. This mechanism is present when the release of the drug 
is due to stresses and state-transition in hydrophilic glassy polymers that suffer swelling when in 
contact with liquid solutions such as body fluids.
47
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 =    
  +    
     (3) 
The m is equally a Fickian diffusion exponent and equals n when the relaxation mechanism is not 
present while both Kd and Kr are constants. Using this model all the 100% of the drug can be 
acknowledged.  
Another important characteristic of the pharmaceuticals is its solid-state chemistry, in view of the fact 
that the existing polymorphism of the particles will have an influence on the stability of the drug and 
on the flowability as well. For lung delivery particles, the carrier should be amorphous because it 
brings out increased dissolution rates, higher water adsorption and also it is crucial for storage 
purposes while the API is preferably crystalline so the bioavailability is maintained. Nonetheless, and 
contrarily to crystalline forms, amorphous compounds are defined by a disorder arrangement of its 
molecules, showing less stability and more reactivity.
30,48
  For that, it is important to access to a 
particle engineering process where these characteristics can be controlled.  The most used technique to 
evaluate the solid-state is the X-ray Diffraction (XRD), which is based on the long-range order 
present, defining the intermolecular spacing of the unit cell and giving subsequently the crystalline 
system.
49
 
 
In order to better understand a process and to reach full efficiency, knowledge at a theoretical level is 
advantageous, especially with the application of a statistical method like design of experiment (DoE). 
DoE is useful to obtain precise data and information of a process without the need of a large amount of 
experiments and associated costs. For instance, using a fractional factorial design it is possible to test 
parameters based on the obtained results and perform a screening. On the other hand, by performing a 
full factorial design the variables interaction can be studied. This kind of study is performed by an 
analysis of variance (ANOVA), which is going to test whether the difference between groups’ means 
are significant or not by comparing variances of the distributions. Basically, the variances are tested 
for statistical significance, and if significant the null hypotheses (all the groups are considered the 
same) is rejected and it is possible to admit that the means are different from each other.
50
 
 
1.5 Poly (lactic-co-glycolic acid) 
Poly (lactic-co-glycolic acid) (PLGA) (Figure 1.5) is used as a biodegradable slow-release polymer, it 
is physically strong, highly biocompatible and bioabsorbable  and also allows an effective 
encapsulation of all kinds of drugs, proteins and various other macromolecules such as DNA, RNA 
and peptides.
51,52
 Additionally, it was approved by the FDA (Food and Drug Administration) for drug 
targeting in the year 2000, being one of the first among all the new minimally invasive protein 
delivery system options, which makes it one of the most promising materials in medical and 
biotechnological research with high commercial interest.
53,54
 PLGA has been the focus of extensive 
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research for release of therapeutic proteins and it is the most popular among the various available 
biodegradable polymers because of its long clinical experience, favorable degradation characteristics, 
bioadhesive properties and possibilities for sustained drug delivery.
51,53
 
 
Figure 1.5 - PLGA structure, with the lactic acid between the left-side brackets and the glycolic acid between the 
right-side brackets. x and y represent the number of times the unit it repeated. 
 
A main influence on the release is the polymer biodegradation. PLGA’s ester backbone undergoes 
hydrolysis in aqueous environments, such as body fluids, and the polymer eventually degrades to 
lactic and glycolic acid monomers with well-established compatibility and safety profile since the 
products are nontoxic, noncarcinogenic, and nonteratogenic.
54–56
 Lactic acid is converted to pyruvate, 
which is degraded in the Krebs cycle via acetylating of coenzyme A, and carbon dioxide, which is 
mainly eliminated by respiration. Part of the glycolate is excreted directly via the urine while another 
part is oxidized to glyoxylate, which is converted to glycine, serine and pyruvate.
53
 
The presence of a drug may change the mechanism from bulk erosion to surface degradation. In 
general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, 
increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to 
surface ratio of the particles. In spite of that, higher content of glycolic acid leads to quicker rates of 
degradation with an exception of 50:50 ratio of PLA/PGA, which exhibits the fastest degradation.
51
   
The Tg (glass transition temperature) of the PLGA copolymers are reported to be above the 
physiological temperature of 37 ºC and hence are glassy in nature, exhibiting fairly rigid chain 
structure. It is known that the Tg decrease with a decrease of lactide content in the copolymer 
composition and with a decrease in molecular weight.
51
 The glass transition temperature for 50:50 
ratio is between 45 and 50
 
ºC. 
55
 
As for the risk of inflammation in situ caused by the polymer, there is some discrepancy in the 
literature as to whether that is true or not. Some groups suggest PLGA particles are inflammatory in 
vitro and in vivo
57
, whereas others have not found this to be the case.
58,59
 The discrepancy between 
these findings may be due to differences in particle fabrication or experimental settings. However, 
given the long clinical history of PLGA and the broad literature reporting PLGA particle uses for 
biomedical applications, it seems unlikely that particles derived from PLGA would trigger potent 
inflammatory responses.
58
 
When the delivery of small proteins and peptides is needed, the production of PLGA particles has 
reduced multiple injections to once every one to three months. During this incubation time, large 
 
10 
 
globular proteins must remain encapsulated at the physiological temperature, and in the dry powder 
state the retention of their structural integrity and biological activity is successful.
8
 Moreover, the 
majority of proteins and peptides are hydrophilic and any attempt to load them into hydrophobic 
PLGA becomes a challenging task, because most methods developed often require the use of aqueous 
media.
8
 
For vaccination purposes, antigen is mostly formulated in PLGA microparticles that are ingested by 
phagocytic cells following administration, resulting in particle degradation and antigen presentation.
52
 
Also, the use of this polymer allows the possibility of the development of a single-dose vaccine due to 
the controlled particle degradation to several weeks.
13
 
 
1.6 Bulking Agents 
In order to obtain particles with the ideal characteristics for lung delivery it is sometimes required the 
use of bulking agents and dispersibility enhancers. Ideally, bulking agents will cover the particles 
during their formation, keeping them from agglomerating in the drying process and also during the 
storage
60
, hence decreasing the bulk density and increasing the dispersibility.
61
 One the most used in 
the literature is L-Leucine (Figure 1.6 (a)), a nontoxic and nonirritant amino acid, known to improve 
flowability and dispersibility.
62
 It was proved that the addition of leucine improved FPF given that it 
reduced the cohesiveness and coalescence of the particles.
37
 
Another option is the use of cholesterol (Figure 1.6 (b)), a neutral lipid that because of its hydrophobic 
nature reduces the absorption of the ubiquitous vapor leading to a reduction in the aggregation and the 
adhesion of particles. Besides, it is biocompatible and it is easily metabolized, being cleared out by 
direct absorption by either epithelial cells or by macrophage uptake.
63
 
 
 
Figure 1.6 - L-leucine (a) and cholesterol (b) structures. 
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1.7 Particle Production 
There are several known methods to produce particles for inhalation and those can be divided into two 
groups: the top-down (large particles are mechanically broken down to smaller ones) and the bottom-
up (particles are formed from the molecular level).  
Milling is based on a top down approach since it consists on the grinding of bulk crystallized particles 
into small ones with the use of mechanical forces such as pressure, friction, attrition, impact or shear.
25
 
In order to produce particles for inhalation, there are three types of mills that can be used, fluid-energy 
mills (jet-milling), high-peripheral-speed mills (pin-mill) and ball mills. The most used technique is 
jet-milling where high-pressure nitrogen is used to provide a sonic velocity to solid particles, which 
makes them collide and fracture into particle down to 1μm. Even though it is considered a traditional 
particle production technique with a low cost associated, it is inadequate when it comes to particle 
production since the control of size distribution is limited.
64
 Also the process might change the 
physicochemical properties of the material, turning the surface of fractured crystals amorphous.
31
 
The bottom-up processes tend to be more sophisticated and complex, and produce particles with a 
better control of its characteristics. In this case, the manufacturing methods involve the use of an 
antisolvent or are based on solvent evaporation as is spray-drying, the most used and studied solvent 
evaporation technique.
65
 Spray drying is very rapid, convenient and has very few processing 
parameters, making it suitable for industrial scalable processing and it also provides stability and 
biological activity for the API. In this process, drug/protein/peptide loaded microspheres are prepared 
by the means of an atomization of the feed solution into a spray, which later enters in contact with 
heated air in a drying chamber forming a dry powder. The nature of solvent used, temperature of the 
solvent evaporation and feed rate affect the morphology of the microspheres. The disadvantages of 
this process is the adhesion of the microparticles to the inner walls of the spray-dryer, turning the 
yields insufficient, and the possible degradation of heat-sensitive drugs.
66,67
 
 
 
1.8 Supercritical Fluid Technology 
More recently, alternative particle production methods using supercritical fluids, especially 
supercritical CO2 (scCO2), have been proposed to overcome some limitations. Conventional methods 
usually require large amounts of organic solvents and thus require additional extensive purification 
steps to remove the residual solvent. When it comes to using scCO2, organic solvents can be 
minimized or eliminated easily, since scCO2 has a high affinity for them which enables their removal. 
A rapid expansion of the CO2 using a pressure drop leads to the clustering  of CO2 molecules inside 
the liquid polymer, expanding it and inducing pore formation, making the system suitable for drug 
deliver.
5,51
 Moreover, the morphology and porosity can be easily altered by changing operation 
parameters such as pressure, temperature and gas release rate.
68
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Supercritical Fluids (SF) are gases or liquids that are above their critical temperature and pressure, and 
that present characteristics of both states. In one hand they have the density of a liquid, which shows 
advantageous solvation power, while in the other hand they have the viscosity of a gas with an 
associated high diffusivity. Since these aspects are very changeable near the critical point, it is easy to 
control both of them by a slight change in pressure/temperature.
69
 Also, near the critical point the 
compressibility and the heat capacity are much higher than in other conditions.  
Carbon dioxide is the most used gas as a SF, since it is nontoxic, nonflammable, inexpensive and 
readily available in high purity from a variety of sources. Because it is a gas at normal pressure by 
simply reducing the pressure of the system, it is possible to easily separate the solvent and residues 
from the polymer, leading to highly pure materials.
70,71
 Besides, it has a low critical point (31.1
o
C/73.8 
bar)(Figure 1.7), which is suitable to use with heat-sensitive materials and can reduce manufacturing 
complexity and energy.
72
 
 
Figure 1.7 - Phase diagram of CO2 adapted from Leitner W. et al.
73
 
 
There are several particle production techniques that use supercritical fluids, such as supercritical fluid 
extraction where particles are produced when a solution is brought into contact with scCO2 in a semi-
continuous method
74,75
, rapid expansion of supercritical solutions (RESS) where the solid material is 
dissolved in scCO2 and the solution is expanded by depressurization, leading to a fast decrease of 
temperature that will induce supersaturation and consequently microparticle formation
48,76
 and 
particles from gas saturated solutions (PGSS)
77,78
 that consists in two steps: the saturation of a solution 
with CO2 and the mixture’s expansion through a nozzle into a spray tower. 
1.9 Supercritical Assisted Atomization 
Supercritical assisted atomization is proposed and patented by E. Reverchon in US 7276190B2
79
 to 
overcome some of the problems associated with other SF techniques, for instance, some antisolvent 
precipitation processes (e.g. SAS) cannot be used with water-soluble compounds or the fact that RESS 
requires a big amount of CO2 with low productivity.
80
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SAA is based on the solubility of controlled quantities of scCO2 in a liquid solution containing the 
drug and excipient. The mixing happens in a heated saturator with a large contacting surface, assuring 
a high residence time and a near-equilibrium solubilization of the CO2. The gaseous properties of 
scCO2 allow it to diffuse into the amorphous regions of polymers where it enters into the free volume 
between the individual chains. The chain separation increases, enhancing the mobility as a result and 
inducing a proper mixing. This lowers the Tg of amorphous polymers, enabling them to be liquefied 
and since it is reversible, the Tg returns to the original value upon the complete removal of the scCO2.  
The solution is atomized through a nozzle (thin-wall injector) into a precipitator in the form of a spray. 
The CO2 works as a cosolute, since it dissolves itself in the liquid solution and it also works as a 
pneumatic agent, atomizing the solution in fine droplets (pneumatic atomization). After that there is a 
second atomization due to the CO2 expansion existing in the fine droplets interior (decompressive 
atomization) (Figure 1.8).
56,81
  
 
Figure 1.8 - Representation of SAA’s double atomization: pneumatic atomization (left-side) and decompressive 
atomization (right side), adapted from Porta, G. Della et al.
81
 
 
One important factor to keep in mind is the full solubilization of the scCO2 in the liquid solution, and 
that is going to depend on such factors as the pressure and temperature because those are related to the 
high–pressure vapor liquid equilibria (VLE). Moreover, the presence of the solute might also induce 
some modifications and that has to be taken into account because in order to have a successful 
atomization a single-phase should be formed in the saturator.
82,81
 Nonetheless, when one is working 
with a complicated ternary mixture it is known that by using high pressure and temperature, it 
becomes easier to avoid a two-phase behavior.
83
 Another problem is the use of aqueous solutions due 
to the low solubilization  of CO2 in water, but that can be resolved with the use of an organic solvent 
and the reduction of water percentage to a minimum.
82
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In this work composite particles using PLGA as an excipient were produced using SAA. In one hand 
BSA was used as a model antigen for security reasons, and L-leucine as a bulking agent in order to 
develop pulmonary vaccines. In the other hand sildenafil-loaded dendrimers were encapsulated to 
produce nano-in-micro particles to treat pulmonary hypertension using cholesterol as a bulking agent.  
Furthermore all the particles were properly characterized to make sure they were suitable for 
pulmonary delivery.  
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2. Experimental Section 
 
2.1 Materials 
Poly(D-L-lactide-co-glycolide) (PLGA, PURASORB® PDLG 5002A, molar ratio: 50/50, inherent 
viscosity 0.21dl/g) was purchased from PURAC (Gorinchem, Netherlands). Bovine Serum Albumin 
(BSA, Mw 60 kDa), L-Leucine (>98%), cholesterol (94%), acetone (99.8%) and acetonitrile were 
obtained from Sigma-Aldrich. Ethanol (96%) was purchased in Panreac. The sildenafil-loaded 
dendrimers were developed in the host laboratory
1
. Industrial carbon dioxide (purity ≥ 99.93%) was 
obtained from Air Liquide.  
2.2 Microparticles Preparation 
2.2.1  BSA-Loaded Microparticles 
A solution of 0.47% (w/v) PLGA, 0.09% (w/v) BSA and 0.02% (w/v) L-Leucine was prepared with 
83% (v/v) acetonitrile and 16% (v/v) distilled water. While the PLGA was dissolved in part of the 
acetonitrile, both the BSA and Leucine were dissolved in water. After full dissolution the aqueous 
solution was added to the PLGA solution under stirring, with the rest of the acetonitrile added in the 
end.  
2.2.2 SDF-Loaded Dendrimers Encapsulated in Microparticles 
A solution of 0.28% (w/v) PLGA, 0.19% (w/v) cholesterol and 0.14% (w/v) sildenafil-loaded 
dendrimers was prepared with 42.3% (v/v) acetonitrile and 39.5% (v/v) acetone and 18.3% (v/v) 
ethanol. The PLGA was previously dissolved in acetonitrile, the cholesterol in acetone and the 
sildenafil-loaded dendrimers in ethanol.  
2.2.3  SAA Apparatus 
The laboratory scale SAA apparatus, represented in Figure 2.1 consists of two high-pressure pumps to 
deliver the liquid solution (HPLC pump 305 Gilson) and the CO2 (HPLC pump K-501, Knauer) to the 
static mixer. Since the CO2 pump is suitable for liquid solutions, there is a need to liquefy the CO2 in a 
cryogenic bath. Before entering the static mixer the CO2 is heated in an oil bath. The static mixer (3/16 
model 37-03-075 Chemieer) is a high-pressure vessel with a 4.8 mm diameter, 191 mm length and 27 
helical mixing elements that allows the solubilization of the CO2 into the liquid solution  due to its 
high surface packing. In order to control the temperature of the mixture, the static mixer is enrolled by 
heating tapes controlled by a shinko FCS-13A temperature controller (0.2
o
C resolution). The obtained 
mixture is then atomized into the precipitator in the form of a spray by the passage through a nozzle 
with an internal diameter of 150 μm. At the same time, a flow of previously heated compressed air 
enters the precipitator to evaporate the liquid solvent. The visual recipitator is an aluminium vessel 
that operates at near-atmospheric conditions heated by a set of heating tapes that are connected to a 
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Setra pressure indicator (0.1 psig stability). To indicate the pressure of the precipitator an 
EROELECTRONIC LDS controller (0.1
o
C stability) is connected to the top of it. After the precipitator 
there is a heating tape set to make sure the flow remains at high temperatures, thus avoiding heat 
losses and consequent solvent condensation, connected to an Isopad TD 2000 heat controller (0.1
o
C 
stability). The particles will then be collected from a filter (FSI, nylon mono-filament, 1 μm) which is 
placed in a cyclone that helps with the separation between the particles and the CO2-solvent flow. 
 
Figure 2.1 – Schematic representation of the SAA apparatus: (CB) cryogenic bath; (LP) liquid pump; (HB) 
heating bath; (TC) temperatute controller; (M) manometer; (S) saturator; (P) precipitator; (c) cyclone.  
  
2.3 Microparticles Characterization 
2.3.1 Particle size distribution 
The particle size (PS) and the particle size distribution (PSD) were measured by a Morphologi G3 
essentials, a particle analyzer system. In each particle size calculation around 30000 particles were 
considered. Also the span was calculated, a measure of the width of particle distribution, and it 
considers the dv,10, dv,50 and dv,90 (particle diameter in volume corresponding to 10, 50 and 90% of the 
population) as represented in equation 4: 
Span=
           
     
       (4) 
2.3.2 Particles morphology 
The morphology of the produced particles was studied by Scanning Electron Microscopy (SEM) 
equipment from Hitachi, S-2400 instrument, with an accelerating voltage set to 15kV and at 
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magnifications of 5K and 10K. All the samples were dispersed on carbon tape previously attached to 
an aluminum stub and were coated with gold before analysis. 
2.3.3 Bulk density 
Once inside the calibrated cell the powder was maintained 24 h under vacuum to totally dry and degas 
the sample. The cell was then installed into the adsorption apparatus from the adsorption laboratory 
(Faculty of Sciences, University of Lisbon). Bulk density of the microparticles was determined by 
measuring the pressure change of helium in a calibrated volume.  
2.3.4 Differential scanning calorimetry (DSC) 
The differential scanning calorimetry patterns were obtained by treating the samples in a differential 
scanning calorimeter PerkinElmer DSC 7. The samples (10-30 mg) were placed in a holder where the 
temperature was raised from 25
o
C to 300
o
C in a heating rate of 10
o
C/min in nitrogen. 
2.3.5 X-ray diffraction 
X-ray diffraction patterns were obtained by treating the samples in a RIGAKU X-ray diffractometer, 
model Miniflex II. Samples were placed in a holder and analyzed through CuKα radiation (3 KV/15 
mA), with a 2θ angle ranging between 2
o
 and 55
o
 with a scan rate of 1
o
/min. 
2.3.6 Fourier Transform Infra Red (FT-IR) 
FT-IR spectra were carried out on a PerkinElmer spectrum 1000 FTIR coupled with Opus 
Spectroscopy Software with potassium bromide (KBr) tablets containing 20% sample.  
2.3.7 Water Content Determination 
Karl Fischer coulometric titration was used for the determination of water content on the samples. An 
aliquot of the samples was transferred into the titration vessel and titrated with Karl Fischer reagent, 
which reacts quantitatively and selectively with water.  The instrument was composed by the 831 KF 
Coulometer and a 728 stirrer both from Metrohm and by a Pt /-20…70 ºC electrode.  
2.3.8 Drug Loading and Encapsulation Efficiency 
The drug encapsulation was determined by milling a fixed amount of powder and then adding a known 
amount of PBS. The solution was under stirring for 2 h and then was centrifuged at 15000 rpm for 5 
min. The supernatant was collected and the amount of drug was obtained by UV spectroscopy. The 
percentage of encapsulation was calculated from the obtained mass (mr) and the initial mass (mi) as 
represented in equation 5. 
E(%)=
  
  
  (5) 
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2.3.9 Aerodynamic Properties 
2.3.9.1  Emitted Fraction 
To determine the shot weight, which is the amount of powder that is released from the capsules, the 
Dosage Unit Sampling Apparatus (DUSA) is used. The air is drawn by a High Controller Pump model 
HCP5 (Copley) that simulates inhalation and air flow was regulated in a Critical Flow Controller 
model TPK (Copley) until the P1 pressure achieves the 4kPa. The air flow (Qair) was measured with a 
flow meter model DFM3 (Copley) in order to calculate the run time of each capsule using the equation 
6: 
t(s)=
  
            
 x 60 (s/min)  (6) 
Also, there is a need to ensure that P3/P2 ≤ 0.5 in order to guarantee the critical flow.  
The assay consists on the release of 4 capsules (HPMC capsules nº3 Aerovaus) with 30±2 mg of 
powder each from a dry powder inhaler (Plastique 60LPM – Mode 7) and it is performed in triplicate 
as reported in the European Pharmacopeia.
41
 
The emitted fraction (%) uses the weights (mg) of the capsule before and after the assay (mfull and 
mempty respectively) as represented in equation 7: 
 
EF(%)=
            
     
 x 100%   (7) 
 
2.3.9.2  Andersen Cascade Impactor 
The aerodynamic properties of fine particles were carried out using an aluminum Andersen Cascade 
Impactor apparatus (ACI)(Copley) (Figure 2.2). The assay is performed with the same instruments as 
the emitted fraction test, being the capsules prepared equally and the run time calculated using the 
same European Pharmacopeia protocol.
41
  
The assays were performed gravimetrically, so glass microfiber filters (80mm, Filter Lab) were placed 
in all the stages and were weighted before and after the capsules release. In order to obtain the drug 
concentration on each stage, the powder of each filter was then dissolved, the solution was centrifuged 
and its absorbance was read in an UV spectrophotometer (PerkinElmer Lambda 35). Each capsule was 
drawn through the induction port into the ACI at a flow rate of 62±2 L/min for 3.9±0.2 seconds. The 
effective cut-off aerodynamic diameter for each stage of the ACI were: stage -1, 8.6 μm; stage -0, 6.5 
μm; stage 1, 4.4 μm; stage 2, 3.2 μm; stage 3, 1.9 μm; stage 4, 1.2 μm; stage 5, 0.55 μm; stage 6, 0.26 
μm.  
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Figure 2.2 - Experimental set-up to perform ACI (adapted from European Pharmacopeia)
41
. 
 
The fine particle fraction (FPF) was determined by the interpolation of the percentage of the particles 
containing less than 5 μm. The Mass Median Aerodynamic Diameter (MMAD) was determined as the 
particle diameter corresponding to 50% of the cumulative distribution. The Geometric Standard 
Deviation (GSD) was determined using the values of d84 and d16, which represent the diameters of 
84% and 16% of the cumulative distribution as in equation 8: 
 
GSD=    
   
   
  (8) 
2.3.10 Pharmacokinetic Studies  
2.3.10.1 BSA-Loaded Particles 
The in vitro release studies were carried out in phosphate-buffered saline at pH 7.4 (PBS).  60±2 mg of 
sample was introduced in a cellulose ester dialysis membrane (MWCO 100,000, 24 mm x 15 feet dry 
diameter, 1.8 mL/cm, Spectrum Labs) that was suspended in 5 mL of PBS. Samples of 0.5 mL were 
taken at predetermined time points and other 0.5 mL of PBS were added to the suspension and the 
samples.  
2.3.10.2 Dendrimer-Loaded Particles 
The in vitro release studies were carried out in phosphate-buffered saline at pH 7.4 (PBS).  20±2 mg of 
sample was introduced in a SnakeSkin Dialysis Tubing (3.500 MWCO, 22 mm x 35 feet dry diameter, 
34 mm dry flat width, 3.7 mL/cm, Thermo Scientific) that was suspended in 10 mL. Samples of 1 mL 
were taken at predetermined time points and other 1 mL of PBS was added to the suspension and the 
samples.  
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The drug concentration was obtained by UV-visible spectroscopy and the drug-release profiles (%) 
were represented as a function of time.  
The release profiles were modulated using Korsmeyer-Peppas (2) and Peppas and Sahlin (3) 
equations. 
 
2.3.11 Biodegradability Assays 
Biodegradation of microparticles was carried out in the presence of 0.2 mg/mL of lysozyme dissolved 
in PBS 10 mM at 37 
o
C. 2 mg of microparticles were incubated with 1 mL of lysozyme solution under 
horizontal agitation at 50 rpm.  The enzymatic degradation medium was changed every 48 h to restore 
the original level of enzymatic activity. The solution was centrifuged at 13500 rpm for 7 min and the 
supernatant removed. Then the particles were lyophilized and weighed and the process repeated. The 
biodegradation rate is represented as a percentage of the remained weight (Wr) and it is calculated with 
the use of equation 9 where W0 and the Wf are the initial and final particles’ weight, respectively: 
Wr(%)= 100 - 
     
  
 x 100  (9) 
 
2.3.12 Biocompatibility Assays 
In vitro cytotoxicity assays were performed for each cell line available and for each compound 
mentioned above, through the use of purity ≥ 99.93% CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, USA), a colorimetric method for determining the number of 
viable cells. 
At 80 % confluence, cells were harvested and centrifuged. The supernatant was discarded, and the cell 
pellet resuspended in 2 mL of medium. For growth inhibition assays, 0.75*10
5
 cells/mL were plated 
into flat bottomed 96-well plates (Costar, Corning, NY) and incubated  at 37 ºC, 99 % humidity and 5 
% CO2 (v/v). Cell density was evaluated as the total number of viable cells within the grids on the 
hemacytometer (Hirschmann, Eberstadt, Germany) using trypan blue exclusion method. For this 
procedure 350 µL of medium was pipetted to a 2 mL eppendorf together with 50 µL of the 2mL cell 
suspension followed by 100 µL of 0.4 % (v/v) trypan blue solution (Sigma). The hemacytometer was 
loaded and examined immediately under the microscope at low resolution, and cell viability was 
determined through the equation 10. 
 
           
  
 
                   
 
                                      (10) 
After 24 h, the samples were added (after removal of depleted medium), and the cells were incubated 
for an additional 48 h. Subsequently a reaction mix of medium, MTS (3-(4,5-dimethylthiazol-2-yl)-5-
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(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), and PMS (phenazine 
methosulfate) in a ratio of 100:19:1 was added to each well and further incubated for 45 min. During 
this period, MTS is bioreduced into formazan, by dehydrogenase enzymes present in metabolically 
active cells, which in turn is susceptible of being measured at 490 nm absorbance by Tecan Infinite 
F200 Microplate Reader (Tecan, Männedorf, Switzerland), directly from the 96-well assay plate, so 
that the quantity of formazan product measured is directly proportional to the number of living cells in 
culture. The cell viability results for each concentration assayed were normalized relative to the 
control samples and obtained accordingly to equation 11: 
                         
                          
                        (11) 
Before testing the powders, the drug was tested by itself at different concentrations (10, 50, 100 and 
250 nM) and duration (24 and 48 hours). The assays were performed in duplicate. 
2.3.13 Design of Experiment (DoE) 
To understand the effect of some of the formulation variables on the particles size, a design of 
experiment (DoE) approach was adopted using STATISTICA
TM
 software version 10 (Statsoft, Bell, 
Tulsa, Oklahoma). In this case the absence or presence of both L-leucine and BSA was tested, which 
means that 2
2 
experiments were taken into account. All the experiments were made in triplicate and the 
statistical differences in between different formulations was obtained using Factorial ANOVA. The 
analysis was performed considering changes in Dv50, MMAD, FPF and EF.    
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3. Results and Discussion 
To study the production of microparticles for vaccine pulmonary delivery, while BSA was chosen as 
the model protein, since it has already been extensively studied and it also is safer to work with than 
an actual antigen; L-leucine was chosen as the bulking agent. While BSA and L-leucine are soluble in 
water, PLGA is not. The chosen organic solvent to dissolve PLGA was acetonitrile, since it was one of 
the few miscible in water and it also was the “greener” option. The quantity of water in the solution 
was diminished to a minimum, since CO2 is partially soluble in it; therefore, the concentrations of 
BSA/L-Leucine used in the formulation were on their limit of solubility, as well as PLGA’s. 
Meanwhile, to treat pulmonary hypertension, neither the dendrimers nor the cholesterol, the chosen 
bulking agent, required the use of an aqueous solution, and ethanol and acetone were chosen to 
dissolve them respectively.  
 
3.1 PLGA microparticles 
Even though PLGA has been used as a carrier for pulmonary delivery in several research papers, there 
is no literature of it being micronized by SAA. Therefore, the first step of the process was to optimize 
the PLGA microparticles until the best operating conditions were found.  
The temperature was a very important parameter to control due to the low Tg PLGA presents (45-50 
ºC). When the mixture occurs in the static mixer, the temperature needs to be below this value, but yet, 
it has to be above the CO2’s critical temperature (31.1 ºC) and so 40 ºC was used as the set point, 
while the CO2 was heated at 50 ºC. Other problem associated with the temperature was the efficient 
drying of the particles in the precipitator because the acetonitrile and water’s boiling temperature (82 
ºC and 100 ºC respectively) is much higher than the PLGA Tg. It was found that the best temperature 
to be used in the precipitator was around 70 ºC with compressed air entering at nearly 100 ºC. 
Temperatures below that led to wet particles, while temperatures much higher led to formation of 
melted particles. In order to maintain a heated flow until it reaches the cyclone, a heating tape was 
placed right after the precipitator. 
As for the pressure, throughout the assays three different pressures were tested. At first a pressure of 
10 MPa was used, and since the particles still required to be optimized, a higher pressure was tested 
but no differences were noticed. At last, a lower pressure was used (9 MPa) and there was a slight 
improvement in the particles characteristics, such as their size and morphology. 
The gas to liquid ratio was calculated taking into account the volumetric flows and was varied between 
5 and 1.55 but since there was a slight improvement with the higher ratio, the assays proceeded with it. 
Other experimented option was the heating of the cyclone. This would ideally make sure that the 
solvent remained evaporated and the particles were dried. Instead it turned the particles more 
plasticized due to the polymer’s Tg and to the fact that the particles were in contact with the heated 
surface throughout the entire assay.   
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Besides obtaining suitable particles’ characteristics, another problem was the yield of the assays. They 
started out very low (5-10%), but with the optimization of the parameters they started to increase until 
they reached almost the 30%. Initially, two filters were used in the cyclone to improve the amount of 
powder collected, however because the PLGA particles are so small with sizes around the filter’s pore 
diameter, they often obstructed the filter resulting in a fast pressure increase. The only way to perform 
an assay without the rise of pressure was to use a single filter inside the cyclone, which as a drawback, 
increased the amount of lost particles that left with the gaseous flow.  
Table 3.1 shows some of the assays performed only with PLGA that showed major differences in yield 
and morphology.  
 
Table 3.1- Operating parameters of some of the PLGA assays and the respective yields.  
Assay Yield (%) 
Tsat 
(
o
C) 
Tprec 
(
o
C) 
Tpre-cyc 
(
o
C) 
TCO2 
(
o
C) 
Tair 
(
o
C) 
Pressure 
(MPa) 
QCO2/Qsol Ratio
a
 
1 10 n.a. 65 n.a. 180 180 10 5 
2 23.6 45 n.a. 35 100 180 10 1.55 
3 27.9 45 50 35 100 180 10 1.55 
4 14.9 40 70 50 50 100 9 5 
Tsat – Temperature of the saturator; Tprec – Temperature of the precipitator; Tpre-cyc Temperature of the the pre-
cyclone; TCO2 – Temperature of the carbon dioxide; Tair – Temperature of the compressed air; n.a. – not 
available. 
a
QCO2/Qsol ratio was obtained considering volumetric flows 
  
3.1.1 Morphology 
Although the first particles obtained were characterized for having geometric diameters much bigger 
than expected, their numeric diameters were smaller, and this can be explained by the existence of big 
agglomerates that even though were few in number, were large enough to make the geometric 
diameter increase to such high values, represented in Table 3.2. The first two assays showed 
agglomerates so large that only the 10x objective of Morphologi G3 was able to do the analysis, and 
which was probably not being capable of counting the smaller particles. When the most appropriate 
conditions were found, the agglomerates diminished from a diameter of around 200 μm to 10 μm.  
To calculate the particles aerodynamic diameter the bulk density has to be taken into account. Because 
the particles have a small bulk density, when using the Stokes equation (1) to determine the da, the 
values decrease, even getting inside the appropriate range in the last assay.  
 
Table 3.2 – Properties of PLGA microparticles 
Assay Dv,50 (μm) 
Dn,50 
(μm) 
Span 
Bulk 
Density 
(g/mL) 
Da 
(μm) 
1 203.7(10x) 7.26 0.80 
0.19±0.01 
88.8 
3 193.9(10x) 6.38 1.35 84.5 
4 11.25±3.4 5.17±0.30 0.66±0.40 4.9 
Dv,50= Particle volumetric diameter of 50% cumulative distribution; Dn,50 – Particle 
number diameter of 50% cumulative distribution;  
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Also to prove that the Dv50 is due to the presence of agglomerates SEM was performed and the results 
are shown in Figure 3.1. As can be seen in the right side of the image (b) single particles do not have 
diameters much larger than 1μm. In the other hand, they do not seem spherical, but that is because 
when exposed to the electron beam of SEM, the particles tend to melt since they are heat-sensitive and 
lose their original form. Also by analyzing the images obtained by Morphologi G3 (Figure 3.2) it is 
possible to recognize the presence of agglomerates. The images (a;b) are from assay 3 particles and in 
(a) besides the expected particle aggregates there is also possible to see small single particles, while in 
(b) there is a confirmation that these big diameter particles are truly aggregates because their 
individual form is outlined. Comparing these to the images obtained in assay 4 the particle aggregates 
show a smaller size, and the presence of small particles is also confirmed.  
 
 
 
 
 
Figure 3.1 - SEM images of the PLGA microparticles with a magnification of (a) 1,500x and (b)10,000 x 
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Figure 3.2 - Morphologi G3 images of the PLGA microparticles (a;b)  at assay 3 and (c;d) 4. (a;c) and (b;d) used 
magnifications of 20,000 and 50,000 respectively. 
3.1.2 Aerodynamic Performance 
As already mentioned, the MMAD is also an important parameter when it comes to study particles 
suitable for inhalation purposes, and it is determined by the use of the ACI. The obtained result 
regarding the powders distribution is represented in Figure 3.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3- Graphical representation of the powder distribution in the ACI apparatus for the PLGA 
microparticles 
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By observing Figure 3.3 it is clear that most of the dry powder deposits in the induction port (IP), 
which is representing the upper airways, probably because of the aggregates presence and the 
formation of turbulent eddies in the curving zone of the tube, that has as a consequence the aggregates 
impaction. Besides the MMAD, there are other important values obtained through the ACI, such as the 
FPF and GSD. Recurring to the use of DUSA, the ED is also calculated and all these values are in 
Table 3.3 –. Taking into account that the MMAD of the formulation is around 7 μm, it was already 
expected that the FPF would be small, and this also explains the high quantity of powder deposited in 
the IP. The fact that the MMAD is so far from the da is probably due once again to the presence of the 
clogs that are not able to disaggregate when inhaled. Also the powder could not be uniform, leading to 
differences in sizes determined in different techniques. As for the ED, since it is above 98% it means 
that almost all the powder exits the capsule. 
Table 3.3 – Representation of the aerodynamic properties determined by ACI and DUSA for the PLGA 
microparticles. 
 
 
MMAD – Mass Median Aerodynamic Diameter; FPF- Fine particle fraction; GSD – Geometric Standard Deviation; 
ED – Emitted Dose 
 
 
3.1.3 Physical-Chemical Properties 
Given the importance of the solid-state of the particles, both unprocessed and processed by SAA 
PLGA was tested using XRD and the result is in Figure 3.4. They have very similar curves, both 
presenting a broad peak close to 20º showing that PLGA shows an amorphous state after and before 
being processed and thus making it suitable as a carrier.
84
 
 
 
 
 
 
 
 
 
 
In Figure 3.5 are the DSC curves obtained for raw PLGA and PLGA microparticles and they both show 
a peak near the 50 ºC (46.2 ºC and 51.8 ºC respectively), which represents the polymer’s Tg. Before 
and after this peak there is a slight step that represents a difference in the sample’s Cp, and that 
corresponds to the glass transition of the polymer. The slight shift to the right might have been induced 
MMAD (μm) FPF (%) GSD ED (%) 
7.05±1.24 11.72±1.86 2.44±1.05 98.5±0.60 
Figure 3.4 - X-ray Diffraction. (a) unprocessed PLGA; (b) PLGA  microparticles 
0 5 10 15 20 25 30 35 40 45
(b)
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by the micronization in SAA, since it is known that such process sometimes leads to increasing values 
of Tg.
81
 There is a raise in the end of the curve at around 300ºC, which is attributed to thermal 
decomposition of the polymer.
85
 
 
  
 
 
 
 
 
 
Both processed and unprocessed PLGA were analyzed by FTIR (Figure 3.6) in order to understand if 
the polymer was maintained in its conformation. Both spectra present the polymer’s characteristic 
peaks: 3526/3528 cm
-1
 (OH strecthing), 2999 and 2955 cm
-1
 (C-H stretching of CH3 groups), 
1760/1761 cm
-1
 (stretching of C=O) and 1088/1091 cm
-1
 (C-O strectching).
86,87
 
 
 
 
 
 
 
 
 
In order to determine the water content of the particles, a Karl-Fischer test was performed and the 
resulting water percentage in PLGA particles is 0.86±0.07%, making clear that there is an efficient 
drying process. 
Figure 3.6 - FTIR. (a) unprocessed PLGA; (b) PLGA microparticles 
 
Figure 3.5 – DSC of (a) unprocessed PLGA and (b) PLGA microparticles 
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3.1.4 Biodegradability Assays 
The biodegradability of the PLGA particles was followed using solutions with and without lysozyme, 
an enzyme that is present in the lung, and the remaining weight as a function of time is in Figure 3.7. 
The biodegradation rate of the polymer is known to be around a month long, but in this experiment it 
took longer. When lysozyme is present the degradation is a bit faster, with a remaining weight of 
around 20%, while without lysozyme near 40% of the weight remained.  
In spite of the results, a second experiment should be performed, since the original mass was very 
small, so slight differences in weight loss would be hard to notice, especially when the used scale was 
not the most appropriate because the changes within readings were in the apparatus error. Also, a 
longer time of lysozyme exposure should be considered, at least until the two months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2  BSA-loaded microparticles 
When the BSA was introduced in the microparticles, they showed a lot of improvements, yield and 
morphology-wise. Several conditions were tested for the new formulation and as expected the most 
suitable were the same ones used to produce PLGA microparticles. The ones that showed the biggest 
improvement are in Table 3.4 and the first point noticed is the increase in yield. When BSA was 
added, even though it is only 14% of the total mass, it was possible to see the improvements  right 
away, because, besides the quantity, the presence of aggregates were not so evident and also the 
powder presented a better flowability. Since the solution was already at saturating conditions only 
other formulation with a different BSA concentration was tested (7% w/w), but as expected the 
resulting powder showed a decline in quality and quantity. The encapsulation efficiency of BSA in the 
Figure 3.7 – Graphic representation of the PLGA degradation in a solution with and without lysozyme. 
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particles is about 48%. The low value of encapsulation can be due to BSA precipitation while it is 
being pumped until the static mixer. 
Table 3.4 - Operating parameters of some of the BSA-loaded PLGA assays and the respective yields.  
Assay Yield (%) 
Tsat 
(
o
C) 
Tprec 
(
o
C) 
Tpre-cyc 
(
o
C) 
TCO2 
(
o
C) 
Tair 
(
o
C) 
Pressure 
(MPa) 
QCO2/Qsol 
Ratio
a
 
5 16 50 50 40 50 180 10 1.55 
6 23.3 50 90 50 50 100 9 5 
7 29.3 40 70 50 50 100 9 5 
Tsat – Temperature of the saturator; Tprec – Temperature of the precipitator; Tpre-cyc Temperature of the the pre-cyclone; 
TCO2 – Temperature of the carbon dioxide; Tair – Temperature of the compressed air. 
a
QCO2/Qsol ratio takes into account 
volumetric flows 
 
In order to achieve better yields and improve the particles, L-leucine was added to the formulation, for 
the reasons already mentioned in the introduction, and tested at several concentrations being 14% w/w 
the highest possible amount of BSA and leucine combined. In assay 12 of Table 3.5 the particles were 
synthesized only with PLGA and leucine, and the yield went up to 30% so it was expected to see some 
gain in the yield by adding the three components together.  After testing several ratios of leucine and 
BSA, at assay 11 the ideal mixture was found, with the highest acquired yield of 39%. The 
encapsulation efficiency was also calculated and for this formulation there is 59% of BSA 
encapsulation. 
Table 3.5 - Operating parameters of some of the BSA-loaded PLGA assays using leucine and the respectively 
yield. 
Assay 
BSA/Leu 
ratio
a
 
Yield 
(%) 
Tsat 
(
o
C) 
Tprec 
(
o
C) 
Tpre-
cyc 
(
o
C) 
TCO2 
(
o
C) 
Tair 
(
o
C) 
Pressure 
(MPa) 
QCO2/Qsol 
Ratio
b
 
8 31 18.9 40 70 50 50 100 10 5 
9 0.96 19 40 70 50 50 100 9 5 
10 1.69 25 40 70 50 50 100 9 5 
11 0.58 39 40 70 50 50 100 9 5 
12 0 30 40 70 50 50 100 9 5 
Tsat – Temperature of the saturator; Tprec – Temperature of the precipitator; Tpre-cyc Temperature of the the pre-cyclone; 
TCO2 – Temperature of the carbon dioxide; Tair – Temperature of the compressed air. 
aBSA/Leu ratio takes into account 
the used mass. bQCO2/Qsol ratio takes into account volumetric flows. 
 
 
3.2.1 Morphology 
By analyzing the diameters obtained in Table 3.6, there is an obvious difference in the Dv50 of the 
particles with BSA, especially in the early assays. Once again by comparing the geometric and 
numeric diameters, there is a substantial difference justified by the same reason as before: existence of 
a few, yet large, agglomerates. The das, despite being in the suitable particle range, are in its very limit 
and since the improvement in size throughout the assays was not as big as expected, the use of a 
bulking agent was tested.  
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Table 3.6 – Properties of BSA-loaded PLGA microparticles 
Assay Dv,50 (μm) 
Dn,50 
(μm) 
Span 
Bulk 
Density 
(g/mL) 
Da 
(μm) 
5 11.37±0.14 5.29±0.10 0.65±0.02  5 
6 11.15±0.17 5.46±0.15 0.68±0.07 0.19±0.01 4.9 
7 10.53±0.03 3.37±0.21 0.82±0.01  4.6 
Dv,50= Particle volumetric diameter of 50% cumulative distribution; Dn,50 – Particle 
number diameter of 50% cumulative distribution;  
 
Throughout the represented assays in Table 3.7 and by observation of the Dn50, it is possible to agree 
that the more leucine its added, smaller particles are formed. As for the Dv50, the assays with more 
leucine present more suitable diameters than when only BSA and PLGA were in the formulation. 
Also, these diameters are also smaller than the Dv50 obtained for the particles containing PLGA and 
leucine, confirming that both BSA and leucine are important for the particles progress. This way, the 
das are better fitted into the needed range. 
 
 
Table 3.7 - Properties of BSA-loaded PLGA microparticles using leucine. 
Assay Dv,50 (μm) 
Dn,50 
(μm) 
Span 
Bulk 
Density 
(g/mL) 
Da 
(μm) 
8 11.07±0.03 3.80±0.22 1.83±0.57  4.82 
9 10.79±2.39 4.46±0.54 0.74±0.63  4.70 
10 7.38±1.10 2.82±0.45 1.54±0.05 0.19±0.01 3.22 
11 9.39±0.98 2.48±0.54 0.98±0.14  4.09 
12 10.75±0.80 2.63±0.12 0.80±0.13  4.69 
Dv,50= Particle volumetric diameter of 50% cumulative distribution; Dn,50 – Particle 
number diameter of 50% cumulative distribution;  
 
 
Besides differences in size, particles with encapsulated BSA also show differences in its morphology 
and in Figure 3.8 that difference can be noticed with the SEM images. The BSA-loaded PLGA 
microparticles (c;d) show a more spherical form and especially in (d) there are some particles with 
diameters smaller than 1μm. The analysis of the images obtained by Morphologi G3 (Figure 3.9) show 
the differences between particles. The images (c;d) are from BSA/leucine-loaded particles while (a) is 
from BSA-loaded particles and (b) is from leucine-loaded particles. By comparing the micrographs, it 
is clear the reduction in agglomerates from (a) to (d) and while the reduction from (b) to (d) is not 
certain, it is safe to say they both show fewer aggregates. In image (c) are magnified single particles 
that present a spherical form.   
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Figure 3.8 - SEM images of PLGA microparticles and the BSA-loaded PLGA microparticles with a 
magnification of (a) 1,500x (c) 5,000x and (b;d)10,000 x  
Figure 3.9 - Morphologi G3 images of the (a) BSA-loaded PLGA microparticles; (b) Leucine loaded PLGA 
microparticles; (c;d) BSA/leucine loaded PLGA microparticles. (a;b;d) and(c) used magnification of 20,000 and 
50,000 respectively. 
 
33 
 
To understand the aggregates behavior when in contact with a solution replicating the one existing in 
the lung walls, a dispersion was performed into a droplet of a simulated lung fluid, containing the 
same components as the lung mucus. The solution was made taking into account a previously used one 
in the literature for the same use.
88
 In Figure 3.10 is an example of an aggregate that when in contact 
with the solution for 10 min divides itself in smaller aggregates. However, there is no full 
disaggregation at least for the first 20 min.  
 
3.2.2 Aerodynamic Performance 
The particles were then analyzed by ACI, and as expected, the results were better in comparison with 
the microparticles containing only PLGA. Both particles with and without leucine were tested, and the 
resulting distributions are represented in Figure 3.11. The main difference is in the decrease of powder 
deposited in the induction port, even though it is still a higher percentage than desired. Also, some of 
the further stages seem to have a slight raise. To confirm these, the MMAD and FPF were calculated 
and are in Table 3.8. Once again there is a slight difference between the MMAD and the da, probably 
meaning that there is some disaggregation while the particles are inhaled, leading to a smaller MMAD. 
There is an improvement in the FPF and GSD as well, especially when leucine is present, while the 
ED remains high. Although not very high, this value of FPF is within the range obtained for PLGA 
microparticles. 
27,38
  
 
 
 
 
 
Figure 3.10 – Morphologi G3 images from BSA-loaded particles when in contact with a simulated lung 
fluid. (a) t=omin (b) t=10min. Images have a magnification of 50.000x 
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Figure 3.11 - Graphical representation of the powder distribution in the ACI apparatus for the BSA-loaded and 
BSA/Leu-loaded PLGA microparticles.  
 
Table 3.8 - Representation of the aerodynamic properties determined by ACI and DUSA for the BSA-loaded 
PLGA microparticles. 
MMAD – Mass Median Aerodynamic Diameter; FPF- Fine particle fraction; GSD – Geometric Standard Deviation; 
ED – Emitted Dose 
 
Even though it is possible to gather the mass of powder that gets to each ACI stage, the actual amount 
of BSA that is inhaled is not known. For that reason, the powder retained in each stage was dissolved 
and the BSA was quantified. Its distribution is in Figure 3.12 and it takes into account as total mass all 
the BSA that reaches every stage after de induction port, which in this case was 1.3±0.1 mg. This way 
the amount of BSA that reaches the deep lung can be estimated by quantification by UV.
70
 
 MMAD (μm) FPF (%) GSD ED (%) 
BSA 3.7±0.3 17±2 1.9±0.1 97.2±0.8 
BSA/Leu 2.8±0.6 32±2 2.6±0.3 97.5±0.8 
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When leucine is present the distribution of BSA throughout the stages was a bit different, being the 
stage with a cut-off of 4.41μm the one with the biggest quantity. Since the MMAD was decreased and 
the FPF increased, it is normal that more amounts of powder gets furthest, and by analyzing the Figure 
3.11 this stage has a significant deposition. The distribution of BSA considers as a total mass 1.9±0.9 
mg, which is also higher than without the presence of leucine.  
 
3.2.3 Physical-Chemical Properties 
The solid-state of all the produced particles was also studied. Both raw and processed BSA were 
represented in Figure 3.13, and the two curves have two peaks at about 7 and 20º, which indicates a 
presence of a semi-crystalline compound.
89
  
 
 
 
 
 
 
 
 
Figure 3.13 - X-Ray Diffraction. (a)  unprocessed BSA; (b) BSA microparticles; 
Figure 3.12 - Graphical representation of the BSA distribution in the ACI apparatus for the BSA-
loaded and BSA/Leu-loaded PLGA microparticles. 
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In Figure 3.14 the XRD curves of all the produced formulations are represented and it is possible to 
understand how the encapsulation of both leucine and BSA affect the particles solid-state. 
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When BSA is encapsulated the peak is no longer noticed, which could indicate that all the BSA is 
within the polymer. When the leucine is added the curve gains two sharp peaks, which are proven to 
be from leucine by observation of curves. The curve (c) represents the XRD for raw leucine, which 
shows a crystalline form, and that is confirmed by the appearance of its peaks (6.12º, 24.39º and 
30.61º).
90
 However, when it is encapsulated in PLGA a new peak at about 20º appears which might 
indicate a structural change, while the peak at about 5º remains in the same position. When leucine is 
present in a small fraction, it tends to lose its crystalline form, which explains the fade of its peaks 
especially when BSA is encapsulated as well, because it has a very low concentration in this 
formulation.
91
 Nonetheless, the fact that the peaks are still noticed indicates that leucine does not lose 
entirely its crystalline form.
91
 
 
Figure 3.14 – X-Ray Diffraction. (a) PLGA microparticles; (b)  BSA microparticles; (c)Leucine ; (d) PLGA-
BSA microparticles; (e) PLGA-Leu microparticles ; (f) PLGA-BSA-Leu microparticles. 
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The DSC curves give complementary information of the XRD as can be seen in Figure 3.15. In all the 
DSC curves for PLGA, there is a peak near 50 ºC corresponding to the Tg of the polymer. Curve (b) 
presents a broad peak around 70 ºC, which is attributed to the melting point of raw BSA. Around this 
temperature, it is also expected to have a peak related to the reversible unfolding of protein chains. 
Also, there is a sharper peak at 225 ºC due to the full denaturation of the protein. However, by 
analyzing curve (c), this peak along with the broad one disappear suggesting the stability enhancement 
of the protein when entrapped in PLGA. Also, it might indicate the protein’s dispersibility in the 
polymer’s matrix.
91
 The peak related to the polymer’s Tg suffers a slight shift to the right (from 51.8 
ºC to 53.7 ºC) which might be due to the overlap with the BSA’s broad endothermic peak.
85,92
 When 
leucine enters the formulation (d;e) a new peak appears at about 218 ºC that is correspondent to the 
leucine’s decomposition.
93
 Unlike BSA, this peak appears when leucine is micronized with PLGA and 
with both PLGA/BSA, which indicates the presence of a crystalline form, supporting the results 
obtained by XRD. The peak correspondent to PLGA suffers once again a shift (54.8 ºC in (d) and 55.5 
ºC in (e)) indicating once again one possible interaction with leucine that leads to an increase in the Tg. 
 
 
 
 
 
 
 
 
 
Figure 3.15 - DSC of (a) PLGA microparticles; (b) raw BSA; (c) BSA-loaded PLGA microparticles; (d) 
Leucine-loaded PLGA microparticles; (e) BSA/leu-loaded PLGA microparticles. 
By the observation of the FTIR spectra in Figure 3.16 it is possible to notice that when the powder is 
constituted by PLGA and BSA there is an appearance of two peaks at 1655 and 1543 cm
-1
, which 
correspond to the amide I (C=O stretching) and amide II (N–H bending) respectively. The PLGA peak 
correspondent to the OH suffered a shift from 3528 to 3302 cm
-1
. The rest of the BSA peaks are 
masked by the polymer’s peaks, which is understandable since the ratio of BSA and PLGA is near 
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When leucine is added to the PLGA formulation the FTIR spectra (Figure 3.17) presents two new peaks 
observed at 1586 and 1522 cm
-1
, which are associated to stretching vibrations of CO2
-
. These peaks 
suffered a minor shift to the left when compared to the leucine spectrum probably due to some 
conformational change. Also, the peaks at 3000 and 2955 cm
-1
 show a larger band which may happen 
by the influence of leucine’s peaks at 2957 cm
-1
 which is due to asymmetric stretch of CH2 group. The 
same happens when both BSA and leucine is added, and that can be confirmed by comparing it with 
the PLGA-BSA spectrum. Since both BSA and leucine present peaks between 1490 and 1650 cm
-1
 it is 
possible to see an increase of peaks in that area making it harder to identify them. As for the PLGA 
peak at 3528 cm
-1
, it disappears when leucine is added, which might mean that there is some kind of 
bonding between the molecules.
94
 
 
Figure 3.16 – FTIR. (a) PLGA microparticles; (b) BSA; (c) PLGA-BSA microparticles; (d) PLGA-BSA Leu 
microparticles 
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As for the particles’ water content, the percentages of all the formulations are represented in Table 3.9 
and in all of them it is safe to say that there is very few water in the particles, which reveals the drying 
efficacy of the SAA. Normally, the formulation with less water is the one that only contains PLGA, 
since this polymer is hydrophobic. Overall, when BSA and leucine are integrated in the formulation, 
the water content increases because these two compounds are hydrophilic. However, the particles with 
both leucine and BSA present the smallest percentage and this can be justified by the less formation of 
aggregates when in comparison with the other two formulations. Since the particles are looser they 
tend to dry more easily.  
Table 3.9 – Water content values for the PLGA, BSA-loaded, Leucine-loaded and BSA/leucine-loaded PLGA 
microparticles 
 PLGA BSA/PLGA Leu/PLGA BSA/Leu/PLGA 
Water content (%) 0.86±0.07 2.3±0.2 1.3±0.3 1.3±0.2 
 
3.2.4 Pharmacokinetic Studies 
 By performing the pharmacokinetic studies it is possible to examine the BSA-loaded microparticles 
and to study the mechanism of its controlled release. The release curves were fitted using two different 
equations as represented in Figure 3.18 and Table 3.10. The Korsmeyer and Peppas equation (2) is only 
Figure 3.17 - FTIR. (a) PLGA microparticles; (b) Leucine; (c) Leu-loaded PLGA microparticles; (d) 
BSA/Leu-loaded microparticles 
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suitable for 60% of the release and by the analysis of the n it can be concluded that when leucine is 
present the release is controlled by mostly Fickian diffusion (n=0.39) while when it is not present the 
swelling effect is the main cause for the BSA’s release.
47
 This might be explained by the interaction 
between leucine and PLGA that allows for an easier diffusion of BSA due to steric effects. Also, these 
particles have a slight decrease of agglomerates, meaning that the particles are looser and facilitate the 
BSA diffusion. Furthermore, in image (c) where the first two hours are represented, it is possible to 
see that the release when leucine is present is faster, releasing about 50% in a couple of hours while 
without it the 50% release is achieved at about 18hours.  Meanwhile, with the use of the Peppas and 
Sahlin equation (3), which is already suitable for the 100% of release, both diffusion exponents lead to 
a Fick’s diffusional release, as seen in image (b). Even though Fickian’s diffusion is characterized for 
values of n<0.43, and the BSA release without leucine has a n=0.47, it is safe to admit that diffusion in 
the main present factor. Although both formulations have a different release rate, in both cases the 
100% is achieved nearly 60hours within.  
 
Figure 3.18 - Release profiles on the first 60% of BSA (a;c) and on the 100% release of BSA(b )adjusted with 
Kormsmeyer and Peppas equation and Peppas-Sahlin equation respectively. A zoom of the first two hours 
release is represented in (c). 
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Table 3.10 – Kinetic values obtained from the Korsmeyer Peppas and Peppas & Sahlin equations for the BSA-
loaded and BSA/Leu-loaded PLGA microparticles- 
Microparticles Korsmeyer Peppas Peppas & Sahlin 
 R
2
 k n R
2
 kd kr m 
BSA/Leu 0.9467 0.0060 0.3969 0.9792 0.0165 -0.0017 0.3389 
BSA 0.9907 0.0031 0.8500 0.9683 0.0212 -7E-6 0.4742 
 
 
3.2.5 Biodegradability Assays 
The degradation profiles of microparticles loaded with both BSA and leucine can be observed in Figure 
3.19. The degradation rate is very similar to the PLGA microparticles, with a higher weight loss when 
lyzozyme is present and with a remaining 60% weight when not present. This slow degradation can be 
explained for the same reasons said before for the PLGA microparticles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 - Graphic representation of the BSA/Leu PLGA microparticles degradation in a solution with 
and without lyzozyme. 
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3.2.6  Biocompatibility 
In order to confirm that the microparticles were not toxic to cells, a biocompatibility assay was 
performed using lung cells, the desired target. By the analysis of the results represented in Figure 3.20 
it is clear that both BSA and PLGA are not toxic, once the percentages are all very close to the 100%, 
and that was already expected since they are known for their biocompatibility. Besides the produced 
microparticles show full cell viability, confirming that the SAA technique does not affect the 
components bioavailability.   
 
3.2.7 Design of Experiment 
In order to observe and actually confirm the effects of the addition of BSA and leucine, a design of 
experiment was performed and analyzed with the use of statistics. The variables that suffered a major 
difference were the MMAD, FPF and Dv50 and these were the studied ones. With the analysis of the 
tables ahead  it is possible to assume that for a significance value lower than 5%, MMAD is affected 
by the addition of BSA and leucine, as well as by the addition of both together (Table 3.11). The lowest 
p-value is obtained with the addition of BSA, being this factor the one that leads to the highest 
improvement of the MMAD. In Figure 3.21 is the effect of the addition of both BSA and leucine, and it 
is possible to see the big decrease of the MMAD when adding BSA and leucine, being the smallest 
MMAD the one with all the components. 
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Figure 3.20 – Graphic representation of the BSA, PLGA and BSA/leu-loaded PLGA microparticles effect in 
cell viability.  
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Table 3.11 - ANOVA testing the effects of the parameters on MMAD for a significance level of 5%. p-values 
marked with * mean p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When it comes to the FPF, taking into account the p-value in Table 3.12, the addition of BSA is the 
only factor that actually as an impact, which can also be seen in Figure 3.22 as the value increases in 
about 10 units.  
Table 3.12 - ANOVA testing the effects of the parameters on FPF for a significance level of 5%. p-values 
marked with * mean p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
 
 
 
 
Effect SS 
Degree of 
freedom 
MS F p-value 
Intercept 256.69 1 256.69 461.57 0.0000 
BSA 12.69 1 12.69 22.82 0.0014** 
Leu 9.05 1 9.05 16.27 0.0038** 
BSA/Leu 6.31 1 6.31 11.34 0.0098** 
Error 4.45 8 0.56   
Effect SS 
Degree of 
freedom 
MS F p-value 
Intercept 2236.14 1 2236.14 61.99 0.0000 
BSA 269.14 1 269.14 7.46 0.0257* 
Leu 27.09 1 27.09 0.75 0.4114 
BSA/Leu 17.93 1 17.93 0.50 0.5007 
Error 288.56 8 36.07   
BSA*Leu; LS Means
Current effect: F(1, 8)=11,342, p=,00982
Effective hypothesis decomposition
Vertical bars denote 0,95 confidence intervals
 Leu
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Figure 3.21 – Effect of BSA and leucine in the particles MMAD 
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The Dv50 is affected by the adittion of BSA and leucine, but leucine is the factor that most contributes 
to the decrease of the diameter as seen in Table 3.13. In Figure 3.23 is represented the effect of leucine 
and the difference is very high, with a decrease of nearly 8 μm in diameter. The ED was also 
evaluated, but since there were no major differences between assays there is no special effect on it 
from any of the additions, as confirmed in Table 3.14. 
Table 3.13 - ANOVA testing the effects of the parameters on Dv50 for a significance level of 5%. p-values 
marked with * mean p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
 
  
 
 
 
 
 
 
 
 
Effect SS 
Degree of 
freedom 
MS F p-value 
Intercept 1376.45 1 1376.45 1887.55 0.0000 
BSA 7.91 1 7.91 10.84 0.0109* 
Leu 12.77 1 12.77 17.52 0.0030** 
BSA/Leu 0.14 1 0.14 0.19 0.6766 
Error 5.83 8 0.73   
BSA; LS Means
Current effect: F(1, 8)=7,4615, p=,02578
Effective hypothesis decomposition
Vertical bars denote 0,95 confidence intervals
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Figure 3.22 - Effect of BSA in the particles FPF 
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Table 3.14 - ANOVA testing the effects of the parameters on ED for a significance level of 5%. p-values 
marked with * mean p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
 
 
 
 
 
 
 
3.3 Dendrimer-loaded microparticles 
When the formulation was based on the encapsulation of sildenafil-loaded dendrimers in PLGA 
microparticles at first, leucine was used as a bulking agent, and water, ethanol and acetonitrile were 
the chosen solvents. However, the particles did not show the desirable characteristics and the obtained 
yield was very low. For that reason, cholesterol was considered as the replacing bulking agent, which 
was advantageous, considering that it dissolved itself in acetone, permitting the exclusion of water 
from the solution. Since the amount of sildenafil-loaded dendrimers was not large, the first assays 
were performed only with PLGA and cholesterol. Then, the PUREG4 dendrimers were added, and 
when the parameters were all set the sildenafil-loaded dendrimers were encapsulated.   Two types of 
dendrimers were used, etil-oxazoline [PureG4EtOx] and metil-oxazoline [PureG4MeOX] dendrimers. 
With the use of both of them it is possible to understand the effect of their size in the particles 
Effect SS 
Degree of 
freedom 
MS F p-value 
Intercept 115012.9 1 115012.9 68392.22 0.0000 
BSA 0.1 1 0.1 0.03 0.8630 
Leu 0.4 1 0.4 0.24 0.6374 
BSA/Leu 5.1 1 5.1 3.01 0.1207 
Error 13.5 8 1.7   
Figure 3.23 – Effect of leucine in the particles Dv50  
Leu; LS Means
Current effect: F(1, 8)=17,515, p=,00306
Effective hypothesis decomposition
Vertical bars denote 0,95 confidence intervals
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characteristics. As for the sildenafil encapsulation efficiencies, for the MEOx-SDF microparticles a 
percentage of 42.4% was obtained while the EtOx-SDF microparticles had an encapsulation 
percentage of 31.8%  All the performed assays are in Table 3.15 as well as the characteristics used in 
each one of them.  
Table 3.15 - Operating parameters of the dendrimers-loaded PLGA assays and the respective yields.  
Tsat – Temperature of the saturator; Tprec – Temperature of the precipitator; Tpre-cyc Temperature of the the pre-cyclone; TCO2 – 
Temperature of the carbon dioxide; Tair – Temperature of the compressed air.
a
QCO2/Qsol ratio takes into account volumetric 
flows 
 
 
The conditions were all very similar to the ones used with BSA microparticles, but as for the yields, 
those are quite better. The highest obtained yield was for the MeOx-SDF formulation at around 58% 
and it is in concordance with the other yields, since they tended to increase with the sildenafil 
encapsulation and also to be higher with [PureG4MeOx]  than with [PureG4EtOx].  
3.3.1 Morphology 
By analyzing the diameters obtained in Table 3.16, it is possible to see that they are all around the 11 
μm, being the smallest one with the [PureG4MeOx], which consequently presents the smallest 
aerodynamic diameter. When comparing the values obtained for the particles of PLGA/Chol with the 
ones with encapsulated dendrimers, it is possible to see that its addition led to reduced amount of 
aggregates. While PLGA/Chol has high numeric and volumetric diameters, caused probably by the 
existence of more aggregates, all the other formulations present a much smaller numeric diameter, 
confirming the presence of mostly small particles with only a few aggregates. When sildenafil is 
incorporated the resulting diameters remain in agreement given to the fact that both numeric and 
volumetric diameters of EtOx-SDF are higher than the MeOx-SDF.  
Table 3.16 – Properties of dendrimer-loaded PLGA microparticles 
Assay Dv,50 (μm) 
Dn,50 
(μm) 
Span 
Bulk 
Density 
(g/mL) 
Da 
(μm) 
PLGA/Chol 11.87±0.47 7.04±0.02 0.71±0.04 
0.19±0.01 
5.17 
MeOx 9.02±0.27 2.49±0.49 1.3±0.3 3.93 
EtOx 10.27±1.55 3.95±0.44 0.67±0.02 4.47 
MeOx-SDF 9.84±0.20 2.47±1.50 0.7±0.4 4.28 
EtOx-SDF 10.59±0.14 2.88±0.32 0.64±0.06 4.62 
Dv,50= Particle volumetric diameter of 50% cumulative distribution; Dn,50 – Particle 
number diameter of 50% cumulative distribution; Span= (D90−D10)/D50  
 
Assay 
Yield 
(%) 
Tsat 
(
o
C) 
Tprec 
(
o
C) 
Tpre-cyc 
(
o
C) 
TCO2 
(
o
C) 
Tair 
(
o
C) 
Pressure 
(MPa) 
QCO2/Qsol 
Ratio
a
 
PLGA/Chol 44.3 40 70 50 50 100 9 5 
MeOx 51.0 40 70 50 50 100 9 5 
EtOx 57.4 40 70 50 50 100 9 5 
MeOx-SDF 58.3 40 70 50 50 100 9 5 
EtOx-SDF 55.4 40 70 50 50 100 9 5 
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The particles containing the dendrimers were even more sensitive to the electron beam of the SEM 
analyzes and so the images obtained show a lot of melted particles, which lost their form and so it 
became impossible to check on their size or shape. On the other hand, it was possible to obtain the 
Morphologi G3 results as seen in Figure 3.24. There is no noticeable difference between the images, 
because all the diameters are so close to each other. All show single-small particles as well as some 
aggregates with sizes around 20μm.  
 
 
Figure 3.24 - Morphologi G3 images of the (a) Meox; (b) EtOx (c) MeOx-SDF; (d) EtOx-SDF; (e) PLGA/Chol. 
The used magnification was 50,000x. 
 
(a) (b) 
(c) (d) 
(e) 
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3.3.2 Aerodynamic Performance 
The particles were then analyzed by ACI, and the results of the several formulations are presented in 
Figure 3.25.  The particles containing the drug were not tested for a matter of security and also 
because the drug is in such a low percentage that its presence was not expected to change the results. 
They all present similar distributions, being the main problem the high particle deposition in the 
induction port. All the formulations present about 50% or less of particle deposition in the area, being 
the highest value the one for PLGA/Chol particles, which was already expected considering the 
calculated diameters. Both dendrimers show a similar percentage deposition in all the stages of the 
ACI, and also the associated error for the MeOx particles is high, indicating the lack of particles 
uniformity.    
 
 
 
 
 
 
 
 
 
 
Figure 3.25 - Graphical representation of the powder distribution in the ACI apparatus for the cholesterol-loaded 
and dendrimer-loaded PLGA microparticles.  
Analyzing Table 3.8, it is possible to see that the formulation containing dendrimers present a more 
suitable MMAD and FPF, showing that their presence improves the aerodynamic properties of the 
particles. The MeOx formulation presents the best MMAD and FPF, which is in concordance with the 
calculated diameters and as for the distribution throughout the ACI states it is hard to establish a 
connection due to the associated errors.  
Table 3.17 - Representation of the aerodynamic properties determined by ACI and DUSA for the cholesterol-
loaded and dendrimer-loaded PLGA microparticles. 
MMAD – Mass Median Aerodynamic Diameter; FPF- Fine particle fraction; GSD – Geometric Standard Deviation; 
ED – Emitted Dose 
 
 MMAD (μm) FPF (%) GSD ED (%) 
PLGA/Chol 4.55±0.09 16.37±0.09 2.0±0.4 98.7±0.6 
EtOx 3.0±0.7 29±2 2.3±0.3 98.4±0.2 
MeOx 2.57±0.09 36±4 2.41±0.05 94.4±0.8 
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3.3.3 Physical-Chemical Properties 
The solid-state results are in Figure 3.26 and are much different that the ones obtained with the other 
particles. In image (a), where it is represented the PLGA/Chol particles, the curve presents several 
peaks, but since they are not very sharp and also a broad peak is noticed, it is possible to say that the 
compound is semi-crystalline. It is shown that this type of particles exhibited lower specific surface 
energy leading to a better performance in the powder flow and aerosol tests than crystalline 
materials.
95
 That remains visible throughout all the particles, and because there is no XRD information 
on the dendrimers it is possible to admit that their encapsulation does not change the particles solid-
state characteristics.  
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The DSC curves represented in Figure 3.27 all have in common a small peak at about 50 ºC which is 
from the Tg of PLGA. A new sharp peak at 150 ºC appeared, due to the presence of cholesterol.
96
 
When the dendrimers are part of the formulation the cholesterol peak tends to fluctuate within a small 
range, while it also suffers some broadening, indicating its distribution in the polymers mixture.  
 
Figure 3.26 – X-ray Diffraction. (a) PLGA-Chol; (b) MeOX; (c)EtOx; (d) MeOX-SDF; (e) EtOx-SDF 
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Also, the FTIR spectra obtained are in Figure 3.28. When comparing the FTIR spectra of the 
dendrimer-loaded particles with the PLGA/Chol particles, a peak appearance is seen at 1636 cm
-1
 
(1627 cm
-1
 in MeOx-SDF), which corresponds to the C=O from urea. Also there is an increase of the 
band at 3420 cm, (3433 cm in MeOx-SDF) which corresponds to the amino groups of the dendrimers. 
As already noticed the MeOx-SDF shows a slight shift to the left and as for the MeOx, the dendrimer 
characteristic peaks are barely noticed which can be explained by a smaller concentration of it in the 
particles. In the spectra containing sildenafil there is no diference but that was expected since the 
quantity of drug is very small when in comparison with the dendrimer and excipients. 
 
 
 
 
 
 
 
Figure 3.27 – DSC. (a) PLGA-Chol; (b) MeOx; (c) EtOx; (c)MeOX-SDF; (e)EtOx-SDF. 
 
51 
 
4000 3000 2000 1000 0
(e)
(d)
(c)
(b)
Wavelength (cm
-1
)
(a)
 
As for the particles’ water content, the percentages of all the formulations are represented in Table 
3.18. The particles containing only PLGA and cholesterol show the smallest amount of water, what 
was already expected since, they are both hydrophobic and especially because this formulation does 
not use water as a solvent, and that explains the value under the one obtained for PLGA particles. 
However, dendrimers are very hygroscopic and thus tend to gain humidity with time, which was 
probably what happened and why the water content increased relatively to the PLGA/Chol. Despite 
that, all the values remain very low, and it is clear that they all present a very dry state.   
Table 3.18 - Water content values for the PLGA, BSA-loaded, Leucine-loaded and BSA/leucine-loaded PLGA 
microparticles 
 PLGA/Chol MeOx EtOx 
Water content (%) 0.49±0.04 2.37±0.06 1.98±0.07 
 
3.3.4 Pharmacokinetic Studies 
In order to study the release of the SDF from the micoparticles, the pharmacokinetic studies were 
performed. The Korsmeyer and Peppas equation (2) is represented in Figure 3.29 while the kinetic 
values obtained from it are in Table 3.19 and by the analysis of the n it can be concluded that either 
with MeOx and EtOx the release is controlled by mostly Fickian diffusion. Also, in images (c;d) 
where the first few hours are represented, it is possible to see that the release whit a pH of 5.5 is faster, 
releasing about 50% in less than an hour while with a pH of 7.4 the 50% release is achieved at about 2 
hours. That can be justified by the polymer’s faster degradation at acidic pH, since this condition tends 
to catalyze the breakage of the ester linkage of PLGA, leading to its erosion.
97
 With this it becomes 
Figure 3.28 – FTIR.  (a) PLGA-Chol; (b) MeOX; (c) EtOx; (d) MeOX-SDF; (e) EtOx-SDF 
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much easier for the dendrimers to release themselves in the solution by diffusion and consequently 
release the sildenafil.  
 
Figure 3.29 - Release profiles on the first 60% of Sildenafil of (a;c) EtOx-SDF and of (b;d) MeOx-SDF adjusted 
with Kormsmeyer and Peppas equation.  
 
Likewise, with the use of the Peppas and Sahlin equation (3) as showed in Figure 3.30 and Table 3.19, 
the curves are all defined by a Fickian diffusional release. In this formulation the release is much faster 
in the beginning but it eventually slows down since the 100% release is achieved at nearly 80 hours 
within.  
 
Figure 3.30 - Release profiles of Sildenafil of  (a) EtOx-SDF and of (b) MeOx-SDF adjusted with Peppas and 
Sahlin equation. 
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Table 3.19 – Kinetic values obtained from the Korsmeyer Peppas and Peppas & Sahlin equations for the 
dendrimer-loaded PLGA microparticles. 
Microparticles pH Korsmeyer Peppas Peppas & Sahlin 
  R
2
 k n R
2
 kd kr m 
EtOx 5.5 0.9980 0.2680 0.1707 0.9957 0.1790 -0.0008 0.2636 
 7.4 0.9899 0.1350 0.2902 0.9808 0.2380 -0.0137 0.2430 
MeOx 5.5 0.9983 0.2200 0.2233 0.9679 0.2080 -0.0008 0.2159 
 7.4 0.9988 0.1710 0.2289 0.9944 0.2380 -0.0137 0.2430 
 
3.3.5 Biodegradability Assays 
The several formulations were tested for the biodegradability when in contact with lysozyme, an 
enzyme present in the lungs. The remaining weight throughout time is represented in Figure 3.31 and it 
shows information regarding the PLGA microparticles as well as the particles with encapsulated 
dendrimers. After the first 20 hours, there is a slower release, stabilizing at the 40 days. PLGA 
particles show less release than in the other formulations, ending up with a higher mass percentage 
than the others.  
Figure 3.31 – Graphic representation of the biodegradation of PLGA microparticles, PLGA/Chol, MeOx and 
EtOx microparticles  
3.3.6 Biocompatibility 
Before studying the availability of the microparticles, the possible toxicity of the sildenafil at several 
concentrations and activity times was tested. As seen in Figure 3.32 concentrations between 10 nM 
and 100 nM do not present any toxicity to lung cells. However, at concentrations of 250 nM the 
viability percentage presents some decrease, going around the 80% at (a) and 70% at (b). For that, and 
to see the effect of the sildenafil encapsulation, the assays were carried on using sildenafil at a 
concentration of 250 nM and an activity of 48hours.  
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Figure 3.32 - Graphic representation of the 24hour (a) and 48 hour (b) sildenafil effect in cell viability. 
 
The viability of the dendrimers-loaded microparticles was also tested to work as a blank. By the 
analysis of the Figure 3.33 is possible to see that the viability stands near 100% in all the cases, with 
the exception of EtOx-SDF, whose value is near the 140%. Since it is an isolated case, it could just be 
due to higher cell content in the well, associated with a cell seeding error. Also, the viability obtained 
for sildenafil-encapsulated particles in Figure 3.33 is higher than the one obtained for free sildenafil in 
Figure 3.32, which shows how the encapsulation process diminishes the toxicity of the compound, 
possibility due to the controlled release of it. Overall, it is safe to say that all the particles show full 
viability and are not toxic to lung cells. 
 
Figure 3.33 - Graphic representation of the dendrimer-loaded PLGA microparticles; SDF-dendrimer-loaded 
PLGA microparticles and of sildenafil effect in cell viability. 
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4. Discussion 
When taking into account the overall results obtained there are some major aspects that can be noticed. 
In general, the particles showed mean volumetric diameters of about 11 μm, with correspondent 
number distribution diameters between 3 and 7 μm, which showed the existence of large aggregates in 
the powder. With the results obtained by Morphologi and SEM this aspect was confirmed. Even 
though it shows some variance, the present agglomerates affected all the formulations, indicating a 
problem associated with the manufacturing technique. Because PLGA is a polymer with a very low 
glass transition temperature it becomes an obstacle to produce particles with a technique that requires 
reasonably high temperatures. The parameters chosen to proceed with the production were the ones 
that led to the most suitable particles in terms of size, morphology and aerodynamic properties, all 
crucial characteristics to take into account when producing inhalation dry powders, but one must bear 
in mind that these parameters are still affecting the production. Even though the final product presents 
an aspect of a dry powder, it is possible that some melting is happening, making the particles attach to 
each other.  
However, these microparticles present a low density (0.19±0.01 g/mL), which is a major advantage for 
its aerodynamic performance, caused by the CO2 expansion and consequent droplet burst, and affected 
directly the obtained aerodynamic diameters (4.9 μm for PLGA microparticles; 3.22 μm for BSA/leu 
and 3.93 μm for dendrimer/chol formulations). As was already mentioned before, ideally particles 
should have a high diameter associated with a low density, in a way that the macrophages would avoid 
them and still they would have the flowability that would allow them to reach the deep lung. 
98
 
With the results obtained with the ACI, this property is also visible, with values of MMAD between 2 
and 7 μm. Even though some of these values are still higher than desired, some of the powders fit in 
the proper range and are suitable for inhalation
36
, and those correspond to the PLGA microparticles 
with both API and bulking agent. There is a very accentuated difference between the MMAD and FPF 
values obtained for the PLGA microparticles (7.05μm and 11.72% respectively) and than the ones 
with encapsulated BSA/Leu (2.82 μm and 31.73%) and dendrimer/Chol (2.57 μm and 36.46%), 
showing that for both cases the addition of these compounds was in fact crucial. A major concern that 
is visible when performing the aerodynamic tests is the amount of powder that deposits in the 
induction port. Even though this is usual, as already mentioned, the percentage range is under the one 
observed with already obtained inhalation PLGA particles.
99
 It is also known that this deposition is 
highly related mainly to the presence of the aggregates
100,101
 and as a consequence the values of FPF 
obtained were low, with a maximum of 36%. It is known that DPIs of the first generation commonly 
exhibited a relatively low efficiency in terms of the FPF. The efficiency of the microparticles 
entrainment resides on the ability of the DPI to generate forces sufficient to deagglomerate the powder 
and create a high flow, and that becomes hampered when there is such a large amount of 
aggregates.
27,72
 For that reason, and even though the used DPI might not be the most appropriate, the 
 
56 
 
high existence of aggregates is the factor that mainly influences the aerodynamic results because the 
diminishing of agglomerates was accompanied with the improvement of both FPF and MMAD. 
The obtained yields can also be considered small (39% for BSA/leu and 58% for dendrimer/chol 
formulations), but this can be justified by the inefficient recovery of smaller and lighter particles that 
were exhausted by the gas flow and also by the small volumes used in each assay, that allows greater 
loss of particles throughout the apparatus.
102
 This is supported with the increase of yield with the 
formulations with dendrimers that were micronized from an initial solution of higher volume when 
compared with BSA-loaded PLGA microparticles.   
As for the physical-chemical properties of the microparticles, the results obtained from XRD and DSC 
give similar information. When encapsulating BSA, there is no trace of its original peaks, indicating 
its total encapsulation and stability. Some of the leucine and cholesterol peaks remain noticed 
indicating that these compounds do not fully lose their crystalline form. When the dendrimers are 
encapsulated in PLGA/Chol the resulting powder shows a semi-crystalline state where the broad 
PLGA peak is noticed. The FTIR analysis confirmed the presence of the compounds by the 
appearance of characteristic peaks of their functional groups.  
From all the pharmacokinetic studies performed there is a biphasic curve for drug release mainly 
caused by Fickian’s diffusion. Drug in contact with the medium, is released as a function of solubility 
as well as penetration of water into polymer matrix. At this point, there is no appreciable polymer’s 
weight loss and no soluble monomer products are formed.  In the second phase, the water inside the 
matrix slowly hydrolyzes the polymer into soluble monomeric products, creating a passage for the 
entrapped drug to continue to be released by diffusion.
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The biodegradability of the PLGA particles took longer than when the other compounds were present, 
but still all the formulations took more than a month to stop its degradation. This was already expected 
since this polymer is known to take approximately two months to fully degrade, being this value 
dependable on formulation, porosity, surface area and molecular weight.
103
 Besides, the existence of 
aggregates leads to a slower degradation.
104
   
The biocompatibility assays confirmed the expected viability of all the formulations, once all the 
compounds used are known to not have a toxic effect in cells. Moreover, PLGA particles were 
previously tested for its cytotoxicity in lung cells at several concentrations and all showed closely 
100% viability.
105
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5. Conclusion 
As presented in the introduction, the development of dry powders for inhalation stands as an outbreak 
solution to overcome drawbacks associated with drug delivery while the use of sustainable techniques 
represents a production substitute to surpass the environment issues that affect the industry nowadays. 
For that, this work represents a research field that has been increasingly growing and taken into 
consideration worldwide.  
Herein, it was proven that the SAA apparatus is capable of producing PLGA dry powder 
microparticles suitable for inhalation. Throughout the obtained results it is possible to conclude that 
the particles manufacturing process has associated problems, since it is hard to establish a meeting 
point between ideal powder properties and SAA parameters. However, with the addition of an API 
or/and a buking agent those problems can be mildly surpassed.  
Overall, by adding both BSA/leucine and SDF-loaded dendrimers/cholesterol to the PLGA particles, 
these tend to present suitable aerodynamic properties, while maintaining the API stability and 
preventing its thermal degradation during the production process. The particles showed a controlled 
release and biodegrability as well as full biocompatibility confirming that PLGA is a good carrier to 
perform drug delivery to the lungs.  
The addition of the bulking agents did increase the suitability of the particles, by helping out reducing 
the amount of aggregates present in the powder, which was the biggest issue.  
It is also possible to conclude that the best obtained formulation for pulmonary vaccine delivery was 
with BSA/leucine/PLGA, with a MMAD of 2.82 μm, a FPF of 31.73% and a yield of 39%, which 
present fully proper characteristics for inhalation. As for the treatment of pulmonary hypertension the 
most appropriate particles were the ones containing the [PureG4MeOx] dendrimer, since they were 
produced with a yield of 58.23%, with a MMAD of 2.57 μm and a FPF of 36.46%.  
Despite that, it would be preferable to proceed with a further particles optimization in order to 
overcome the problems associated with the aggregation and also the yield, such as the development of 
a better recovery process in order to avoid such powder loss and the improvement of the formulation 
with the use of another bulking agent or polymer. It would also be interesting to study macrophage 
uptake in order to understand if the particles would be able to remain in the lung tissue during the 
entire drug’s release. The next step would be to perform in vivo studies to fully understand the 
microparticles action when inhaled to a living lung.  
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